Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT ID: NCT05781308
Last Updated: 2025-11-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
156 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-04-26
Study Completion Date
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an open-label, randomized, non-comparative, multicentre, phase II study in which NSCLC patients who have progressed following chemotherapy and immunoptherapy are randomized to receive treatment with either paclitaxel and bevacizumab (Arm A), or paclitaxel, bevacizumab and atezolizumab (Arm B). An estimated 156 patients (52 in Arm A, 104 in Arm B) will be enrolled at approximately 40 centres. Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent or another discontinuation criterion is met. For patients in Arm B, continuation of atezolizumab beyond progression is permitted, at the investigator's discretion, if there is evidence of continued clinical benefit. The null hypothesis is progression free survival at 6 months ≤ 50% for Arm B, which is considered not sufficiently clinically meaningful to warrant further study. The alternative hypothesis is that 66% or more of patients in Arm B would achieve progression free survival at 6 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
NCT00021060
Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
+3 more
COMPLETED
PHASE2/PHASE3
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
NCT03836066
Non Small Cell Lung Cancer
COMPLETED
PHASE2
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
NCT00600821
Non-Small-Cell Lung Carcinoma
Adenocarcinoma
COMPLETED
PHASE2
Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC.
NCT04640935
Non Small Cell Lung Cancer
COMPLETED
Paclitaxel-bevacizumab in Advanced Lung Cancer
NCT01763671
Non-squamous Non-small Cell Lung Cancer
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non Small Cell Lung Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: paclitaxel + bevacizumab
Bevacizumab 15 mg/kg and paclitaxel 200 mg/m² intravenously every three weeks until progression.
Group Type
OTHER
Paclitaxel
Intervention Type
DRUG
Paclitaxel 200 mg/m² every 3 weeks
Bevacizumab
Intervention Type
DRUG
Bevacizumab 15 mg/kg every 3 weeks
Arm B: paclitaxel + bevacizumab + atezolizumab
Atezolizumab 1200 mg, bevacizumab 15 mg/kg and paclitaxel 200 mg/m² intravenously every three weeks until progression.
Group Type
EXPERIMENTAL
Paclitaxel
Intervention Type
DRUG
Paclitaxel 200 mg/m² every 3 weeks
Bevacizumab
Intervention Type
DRUG
Bevacizumab 15 mg/kg every 3 weeks
Atezolizumab
Intervention Type
DRUG
1200 mg every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paclitaxel
Paclitaxel 200 mg/m² every 3 weeks
Intervention Type
DRUG
Bevacizumab
Bevacizumab 15 mg/kg every 3 weeks
Intervention Type
DRUG
Atezolizumab
1200 mg every 3 weeks
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Avastin
Tecentriq
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal patient care.
Patients must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.
2. Male or female aged at least 18 years old.
3. ECOG Performance Status of 0 or 1.
4. Histologically or cytologically documented locally advanced unresectable NSCLC (i.e. stage IIIB/IIIC not eligible for definitive chemo-radiotherapy) or metastatic NSCLC (i.e. Stage IV) (per the 8th edition of Union Internationale Contre le Cancer/American Joint Committee on Cancer \[UICC/AJCC\] staging system) of non-squamous histology.
Note: patients with tumours of mixed histology must be classified as non-squamous or squamous based on the major histological component.
5. Patients progressing after treatment with immunotherapy (anti-PD-1 or anti-PD-L1 Ab) and a doublet of platinum-based chemotherapy, given concomitantly or sequentially to the exclusion of any other treatment.
6. Patients without contraindications to bevacizumab.
7. The investigator must confirm prior to enrolment that the patient has adequate tumour tissue available. Tumour biopsy should be exploitable for molecular analysis.
Note: Tumour tissue collected after the patient was diagnosed with metastatic disease is preferred.
Tumour tissue sample must not be from previously radiated locations. Tumour sample must be one block or at least 10 unstained slides of analysable tissue.
If archival tissue is either insufficient or unavailable, the patient may still be eligible upon discussion with IFCT.
8. All patients must have at least one measurable target lesion according to RECIST v1.1. Previously irradiated lesions can only be considered measurable disease if disease progression has been unequivocally documented at that site since radiation and the previously irradiated lesion is not the only site of measurable disease.
9. Life expectancy ≥ 12 weeks
10. Adequate hematologic and end-organ function, defined by the following laboratory test results:
* ANC ≥ 1500 cells/µL (without granulocyte colony-stimulating factor support within 14 days prior to C1D1).
* WBC count ≥ 2500/µL.
* Lymphocyte count ≥ 500/µL.
* Platelet count ≥ 100 000/µL (without transfusion within 14 days prior to C1D1).
* Haemoglobin ≥ 9.0 g/dL (patients may be transfused or receive erythropoietic treatment as per local standard of care).
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN).
* Patients with known Gilbert's disease or hepatic metastasis who have serum bilirubin level ≤ 3 x ULN may be enrolled.
* AST and ALT ≤ 3 x ULN, with the following exception: patients with documented liver metastases: AST and ALT ≤ 5 x ULN; ALP ≤ 2.5 x ULN; or patients with documented bone metastases: ALP ≤ 5 x ULN.
* Serum albumin ≥ 2.5 g/dL.
* aPTT or PTT and PT or INR ≤ 1.5 x ULN. This applies only to patients who are not receiving therapeutic anticoagulation. Patients receiving therapeutic anticoagulation should be on a stable dose for at least 1 week prior to C1D1.
11. Measured or calculated creatinine clearance ≥ 50 mL/min calculated using the local standard method.
Patients must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.
2. Male or female aged at least 18 years old.
3. ECOG Performance Status of 0 or 1.
4. Histologically or cytologically documented locally advanced unresectable NSCLC (i.e. stage IIIB/IIIC not eligible for definitive chemo-radiotherapy) or metastatic NSCLC (i.e. Stage IV) (per the 8th edition of Union Internationale Contre le Cancer/American Joint Committee on Cancer \[UICC/AJCC\] staging system) of non-squamous histology.
Note: patients with tumours of mixed histology must be classified as non-squamous or squamous based on the major histological component.
5. Patients progressing after treatment with immunotherapy (anti-PD-1 or anti-PD-L1 Ab) and a doublet of platinum-based chemotherapy, given concomitantly or sequentially to the exclusion of any other treatment.
6. Patients without contraindications to bevacizumab.
7. The investigator must confirm prior to enrolment that the patient has adequate tumour tissue available. Tumour biopsy should be exploitable for molecular analysis.
Note: Tumour tissue collected after the patient was diagnosed with metastatic disease is preferred.
Tumour tissue sample must not be from previously radiated locations. Tumour sample must be one block or at least 10 unstained slides of analysable tissue.
If archival tissue is either insufficient or unavailable, the patient may still be eligible upon discussion with IFCT.
8. All patients must have at least one measurable target lesion according to RECIST v1.1. Previously irradiated lesions can only be considered measurable disease if disease progression has been unequivocally documented at that site since radiation and the previously irradiated lesion is not the only site of measurable disease.
9. Life expectancy ≥ 12 weeks
10. Adequate hematologic and end-organ function, defined by the following laboratory test results:
* ANC ≥ 1500 cells/µL (without granulocyte colony-stimulating factor support within 14 days prior to C1D1).
* WBC count ≥ 2500/µL.
* Lymphocyte count ≥ 500/µL.
* Platelet count ≥ 100 000/µL (without transfusion within 14 days prior to C1D1).
* Haemoglobin ≥ 9.0 g/dL (patients may be transfused or receive erythropoietic treatment as per local standard of care).
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN).
* Patients with known Gilbert's disease or hepatic metastasis who have serum bilirubin level ≤ 3 x ULN may be enrolled.
* AST and ALT ≤ 3 x ULN, with the following exception: patients with documented liver metastases: AST and ALT ≤ 5 x ULN; ALP ≤ 2.5 x ULN; or patients with documented bone metastases: ALP ≤ 5 x ULN.
* Serum albumin ≥ 2.5 g/dL.
* aPTT or PTT and PT or INR ≤ 1.5 x ULN. This applies only to patients who are not receiving therapeutic anticoagulation. Patients receiving therapeutic anticoagulation should be on a stable dose for at least 1 week prior to C1D1.
11. Measured or calculated creatinine clearance ≥ 50 mL/min calculated using the local standard method.
Exclusion Criteria
13. For women of childbearing potential (including women who have had a tubal ligation), serum pregnancy test must be performed and documented as negative within 14 days prior to C1D1.
14. Women of childbearing potential must remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 6 months after the last dose of study drugs. Women must refrain from donating eggs during this same period. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries or uterus). Examples of contraceptive methods with a failure rate of \<1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method plus spermicide. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
15. Men with female partners of childbearing potential or pregnant female partners, must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of study treatment to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
16. Participant has national health insurance coverage.
1. Known molecular alteration of EGFR, ALK, ROS1, RET, NTRK, MET, NRG1.
2. Patients previously treated by bevacizumab combined with first-line chemotherapy for NSCLC.
3. Patients with a previous treatment by taxane (docetaxel, paclitaxel). A patient with a previous treatment by peri-operative taxane or in association with radiotherapy is eligible if the treatment has been stopped for more than 6 months.
4. Patients previously treated for unresectable stage III NSCLC are not eligible if they progressed during or within 6 months of stopping consolidation immunotherapy. Patients previously treated by peri-operative immunotherapy for stage I, II or III NSCLC are not eligible.
5. Patients with symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases are not eligible. Note: patients with previously treated or untreated brain metastases may participate, provided they are stable (e.g. without evidence of progression by radiographic imaging for at least 28 days before the first dose of study treatment and neurologic symptoms have returned to baseline). Patients must have no evidence of new or enlarging brain metastases or CNS oedema. Patients must have discontinued use of steroids (with a dose \> 10 mg prednisone equivalent daily) at least 7 days before the first dose of study treatment.
6. Spinal cord compression not definitively treated with surgery or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 2 weeks prior to screening.
7. Malignancies other than NSCLC within 3 years prior to randomization, with the exception of those with a negligible risk of metastasis or death, or treated with expected curative outcome (such as adequately treated in situ cervical cancer, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer).
8. Inability to comply with study or follow-up procedures.
9. Pregnant, lactating, or breastfeeding women.
10. Severe infections (including active tuberculosis) within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.
11. Received oral or IV antibiotics (including antifungals) within 2 weeks prior to randomization. Patients receiving prophylactic antibiotics (e.g. for prevention of a urinary tract infection or chronic obstructive pulmonary disease exacerbations) are eligible.
12. Major surgical procedure within 4 weeks prior to randomization, or anticipation of need for a major surgical procedure during the course of the study.
13. Inability to understand the local language (French).
14. Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or that may render the patient at high risk from treatment complications.
15. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
16. Known hypersensitivity or allergy to Chinese hamster ovary cell products or any component of the atezolizumab formulation.
17. Active or history of autoimmune disease with the following exceptions:
* Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study following discussion with IFCT.
* Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study following discussion with IFCT.
* Patients with benign rheumatoid polyarthritis not needing any immunosuppressive systemic treatment.
* Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g. patients with psoriatic arthritis would be excluded) are permitted provided they meet the following conditions:
* Rash must cover less than 10% of body surface area (BSA).
* Disease is well controlled at baseline and only requires low potency topical steroids.
* No acute exacerbations of the underlying condition within the last 12 months requiring treatment with either PUVA (psoralen plus ultraviolet A radiation), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral steroids.
18. Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
19. History of idiopathic pulmonary fibrosis (including pneumonitis), organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on chest computed tomography (CT) scan at screening. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
20. Patients with a known history of a positive test for HIV or known AIDS who have not received effective antiretroviral therapy (ART) for the last 4 weeks and who have an HIV viral load \>200 copies/mL, regardless of CD4+ T-cell count.
21. Patients with known acute viral hepatitis B or C (HBV, HBC) according to serological tests. Patients with serological sequalae of cured viral hepatitis are eligible.
22. Administration of live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to enrolment or at any time during the study, and for 5 months following the last study treatment.
23. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone \> 10 mg/day, cyclophosphamide, azathioprine, methotrexate, thalidomide, and tumour necrosis factor \[TNF-α\] antagonists) within 2 weeks prior to randomization. Patients who have received acute, low dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) may be eligible for this study following discussion with IFCT. The use of inhaled corticosteroids is allowed. The use of mineralocorticoids (e.g. fludrocortisone) for patients with orthostatic hypotension is allowed. Physiologic doses of corticosteroids for adrenal insufficiency may be allowed after discussion with IFCT.
14. Women of childbearing potential must remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 6 months after the last dose of study drugs. Women must refrain from donating eggs during this same period. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries or uterus). Examples of contraceptive methods with a failure rate of \<1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method plus spermicide. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
15. Men with female partners of childbearing potential or pregnant female partners, must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of study treatment to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
16. Participant has national health insurance coverage.
1. Known molecular alteration of EGFR, ALK, ROS1, RET, NTRK, MET, NRG1.
2. Patients previously treated by bevacizumab combined with first-line chemotherapy for NSCLC.
3. Patients with a previous treatment by taxane (docetaxel, paclitaxel). A patient with a previous treatment by peri-operative taxane or in association with radiotherapy is eligible if the treatment has been stopped for more than 6 months.
4. Patients previously treated for unresectable stage III NSCLC are not eligible if they progressed during or within 6 months of stopping consolidation immunotherapy. Patients previously treated by peri-operative immunotherapy for stage I, II or III NSCLC are not eligible.
5. Patients with symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases are not eligible. Note: patients with previously treated or untreated brain metastases may participate, provided they are stable (e.g. without evidence of progression by radiographic imaging for at least 28 days before the first dose of study treatment and neurologic symptoms have returned to baseline). Patients must have no evidence of new or enlarging brain metastases or CNS oedema. Patients must have discontinued use of steroids (with a dose \> 10 mg prednisone equivalent daily) at least 7 days before the first dose of study treatment.
6. Spinal cord compression not definitively treated with surgery or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 2 weeks prior to screening.
7. Malignancies other than NSCLC within 3 years prior to randomization, with the exception of those with a negligible risk of metastasis or death, or treated with expected curative outcome (such as adequately treated in situ cervical cancer, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer).
8. Inability to comply with study or follow-up procedures.
9. Pregnant, lactating, or breastfeeding women.
10. Severe infections (including active tuberculosis) within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.
11. Received oral or IV antibiotics (including antifungals) within 2 weeks prior to randomization. Patients receiving prophylactic antibiotics (e.g. for prevention of a urinary tract infection or chronic obstructive pulmonary disease exacerbations) are eligible.
12. Major surgical procedure within 4 weeks prior to randomization, or anticipation of need for a major surgical procedure during the course of the study.
13. Inability to understand the local language (French).
14. Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or that may render the patient at high risk from treatment complications.
15. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
16. Known hypersensitivity or allergy to Chinese hamster ovary cell products or any component of the atezolizumab formulation.
17. Active or history of autoimmune disease with the following exceptions:
* Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study following discussion with IFCT.
* Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study following discussion with IFCT.
* Patients with benign rheumatoid polyarthritis not needing any immunosuppressive systemic treatment.
* Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g. patients with psoriatic arthritis would be excluded) are permitted provided they meet the following conditions:
* Rash must cover less than 10% of body surface area (BSA).
* Disease is well controlled at baseline and only requires low potency topical steroids.
* No acute exacerbations of the underlying condition within the last 12 months requiring treatment with either PUVA (psoralen plus ultraviolet A radiation), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral steroids.
18. Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
19. History of idiopathic pulmonary fibrosis (including pneumonitis), organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on chest computed tomography (CT) scan at screening. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
20. Patients with a known history of a positive test for HIV or known AIDS who have not received effective antiretroviral therapy (ART) for the last 4 weeks and who have an HIV viral load \>200 copies/mL, regardless of CD4+ T-cell count.
21. Patients with known acute viral hepatitis B or C (HBV, HBC) according to serological tests. Patients with serological sequalae of cured viral hepatitis are eligible.
22. Administration of live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to enrolment or at any time during the study, and for 5 months following the last study treatment.
23. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone \> 10 mg/day, cyclophosphamide, azathioprine, methotrexate, thalidomide, and tumour necrosis factor \[TNF-α\] antagonists) within 2 weeks prior to randomization. Patients who have received acute, low dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) may be eligible for this study following discussion with IFCT. The use of inhaled corticosteroids is allowed. The use of mineralocorticoids (e.g. fludrocortisone) for patients with orthostatic hypotension is allowed. Physiologic doses of corticosteroids for adrenal insufficiency may be allowed after discussion with IFCT.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intergroupe Francophone de Cancerologie Thoracique
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arnaud SCHERPEREEL, Pr
Role: PRINCIPAL_INVESTIGATOR
Institut Coeur Poumon CHU de Lille
Etienne GIROUX-LEPRIEUR, Pr
Role: PRINCIPAL_INVESTIGATOR
Pulmonology & Thoracic Oncology Department APHP - Hôpital Ambroise Paré
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens
Amiens, , France
Site Status
CHU d'Angers
Angers, , France
Site Status
CH Avignon
Avignon, , France
Site Status
CH Côte Basque
Bayonne, , France
Site Status
CHU Besançon - Hôpital J. MINJOZ
Besançon, , France
Site Status
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, , France
Site Status
Hôpital APHP Ambroise Paré
Boulogne, , France
Site Status
CHU Côte de Nacre
Caen, , France
Site Status
CH Cholet
Cholet, , France
Site Status
CHU Gabriel Montpied
Clermont-Ferrand, , France
Site Status
CH Pasteur
Colmar, , France
Site Status
Centre Hospitalier Intercommunal Créteil CHIC
Créteil, , France
Site Status
Centre Georges-François Leclerc
Dijon, , France
Site Status
CHU Dijon
Dijon, , France
Site Status
Chu Grenoble
Grenoble, , France
Site Status
CHD Vendée
La Roche-sur-Yon, , France
Site Status
CH Versailles
Le Chesnay, , France
Site Status
CH Le Mans
Le Mans, , France
Site Status
CHU Lille
Lille, , France
Site Status
CHU Limoges
Limoges, , France
Site Status
Centre Léon Bérard
Lyon, , France
Site Status
Institut Paoli Calmettes
Marseille, , France
Site Status
APHM Hôpital Nord
Marseille, , France
Site Status
Hôpital Européen
Marseille, , France
Site Status
Hôpitaux Privés de Metz Robert Schuman
Metz, , France
Site Status
GHR Mulhouse et Sud Alsace GHRMSA
Mulhouse, , France
Site Status
CHR Orléans
Orléans, , France
Site Status
Hôpital BICHAT
Paris, , France
Site Status
Hôpital TENON
Paris, , France
Site Status
Groupe Hospitalier Paris Saint Joseph GHPSJ
Paris, , France
Site Status
CH Pau
Pau, , France
Site Status
CHU Bordeaux Haut-Lévèque
Pessac, , France
Site Status
Hospices Civils de Lyon - URCOT
Pierre-Bénite, , France
Site Status
CHU Poitiers
Poitiers, , France
Site Status
CH Annecy Genevois
Pringy, , France
Site Status
CHU Rouen
Rouen, , France
Site Status
CHU Saint Etienne
Saint-Etienne, , France
Site Status
Institut de Cancerologie de l'Ouest ICO
Saint-Herblain, , France
Site Status
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
Site Status
HIA Sainte-Anne
Toulon, , France
Site Status
CHU Toulouse
Toulouse, , France
Site Status
CHU Tours
Tours, , France
Site Status
Clinique Teissier
Valenciennes, , France
Site Status
CH Villefranche Nord Ouest
Villefranche-sur-Saône, , France
Site Status
Countries
Review the countries where the study has at least one active or historical site.
France
Related Links
Access external resources that provide additional context or updates about the study.
https://www.ifct.fr/
IFCT website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT-2201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
NCT01351415
COMPLETED
PHASE3
PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy
NCT07014215
NOT_YET_RECRUITING
PHASE2
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT01057212
TERMINATED
PHASE2
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04921358
TERMINATED
PHASE3
Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment
NCT05738317
UNKNOWN
PHASE2
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
NCT00553800
COMPLETED
PHASE2
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
NCT04471428
COMPLETED
PHASE3
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
NCT04958811
ACTIVE_NOT_RECRUITING
PHASE2
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00334815
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02366143
COMPLETED
PHASE3
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer
NCT00578149
COMPLETED
PHASE2
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00003158
COMPLETED
PHASE2
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00085501
COMPLETED
PHASE2
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT00369551
TERMINATED
PHASE1
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
NCT01107444
COMPLETED
PHASE2
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
NCT00130728
COMPLETED
PHASE3
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
NCT02008227
COMPLETED
PHASE3
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
NCT04691817
RECRUITING
PHASE1/PHASE2
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
NCT00480831
COMPLETED
PHASE2
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
NCT00313768
TERMINATED
PHASE2
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
NCT03509584
TERMINATED
PHASE1
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
NCT00544960
COMPLETED
PHASE2
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
NCT02813785
COMPLETED
PHASE3